CN110812407A

CN110812407A - Sihuang dysentery stopping micro-capsule and preparation method thereof

Info

Publication number: CN110812407A
Application number: CN201911155296.3A
Authority: CN
Inventors: 陈艺青; 刘肖娟; 王俊; 谭志坚; 黎剑坤; 符德文; 黄显会
Original assignee: FOSHAN ZHENGDIAN BIOTECHNOLOGY Co Ltd
Current assignee: FOSHAN ZHENGDIAN BIOTECHNOLOGY Co Ltd; Foshan Standard Bio Tech Co Ltd
Priority date: 2019-11-22
Filing date: 2019-11-22
Publication date: 2020-02-21

Abstract

The invention belongs to the field of chicken colibacillosis treatment, and discloses a Sihuang dysentery stopping microcapsule which comprises the following components: soft extract, emulsifier and astragalus polysaccharide; the thick paste is prepared from the following raw materials: coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice, honeysuckle and gardenia. The invention adopts the western medicine preparation of the traditional Chinese medicine, has simple preparation process, does not need to be dried again, saves the production cost, can fully extract the effective components, can cover the inherent bitter taste of the traditional Chinese medicine of the medicine by adding the auxiliary materials to prepare the micro-capsule, improves the mouth feel, and has good dissolubility and high bioavailability. The Sihuang dysentery stopping micro-capsule has the advantages of reasonable proportion, convenient operation, good content uniformity, good stability, high yield, good taste and good treatment effect.

Description

Sihuang dysentery stopping micro-capsule and preparation method thereof

Technical Field

The invention relates to the field of chicken colibacillosis treatment, and particularly relates to a Sihuang dysentery stopping microcapsule and a preparation method thereof.

Background

Colibacillosis in chickens is an acute and chronic bacterial infectious disease of various chickens caused by pathogenic escherichia coli, can occur in various varieties and chickens of various ages, and seriously affects the development of the chicken industry. In recent years, with the continuous scale development of the breeding industry, a plurality of farmers increase the breeding amount blindly, which causes the deterioration of the breeding environment. The chicken can be prevented and treated by medicines after group outbreak, the commonly used medicines are mostly antibiotic medicines, but in recent years, the colibacillus is very easy to generate drug resistance to the medicines, and antibiotics such as penicillin, streptomycin, terramycin, tetracycline and the like have almost no treatment effect. The chloramphenicol, the gentamicin, the norfloxacin and the neomycin have better treatment effect. However, strains which have drug resistance to these drugs have appeared and are increasing, which causes colibacillosis to appear an increasing trend, and causes great economic loss for breeding production. Colibacillosis in chicken is an infectious disease with complex disease conditions, and can be regarded as virus immersion, lung and stomach heat and blood stasis and qi stagnation according to the dialectical demonstration of Chinese veterinarian, and the treatment is suitable for clearing heat and removing toxicity, activating blood and dissipating blood stasis. The traditional Chinese medicine, in particular to the traditional Chinese medicine granules extracted and processed by the modern technology, becomes the development direction of veterinary medicines. The Sihuang Zhili granule is a Chinese medicinal granule prepared by 6 Chinese medicaments of coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice root and the like through the processes of decoction, filtration, concentration, granulation, drying and the like, and has the functions of clearing heat, purging pathogenic fire and stopping dysentery. However, the existing Sihuang dysentery stopping granules show drug resistance; in addition, the dissolution is slow and the palatability is poor when the composition is clinically used.

Therefore, the development of the tetra-yellow dysentery stopping micro-capsule with good palatability, high efficiency and low drug resistance to prevent and treat the chicken colibacillosis is urgently needed.

Disclosure of Invention

The invention aims to provide a Sihuang dysentery stopping microcapsule and a preparation method thereof, and the Sihuang dysentery stopping microcapsule has the advantages of reasonable proportion, low drug resistance, good content uniformity, good stability, high yield, good taste and good treatment effect.

In order to achieve the purpose, the invention adopts the technical scheme that:

a Sihuang dysentery stopping microcapsule comprises the following components: soft extract, emulsifier and astragalus polysaccharide; the thick paste is prepared from the following raw materials: coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice, honeysuckle and gardenia.

Preferably, the Sihuang dysentery stopping microcapsule comprises the following components in parts by mass: 10-30 parts of thick paste, 50-65 parts of emulsifier and 10-15 parts of astragalus polysaccharide; the thick paste is prepared from the following raw materials in parts by mass: 300 parts of coptis chinensis 200-.

Preferably, the emulsifier is selected from one or two of PEG4000 and PEG 6000.

A preparation method of a Sihuang dysentery stopping microcapsule comprises the following steps:

(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water, filtering, and concentrating to obtain soft extract;

(2) mixing emulsifier and astragalus polysaccharide, heating and stirring;

(3) cooling, adding the soft extract while stirring to obtain mixture;

(4) granulating the mixture, and sieving to obtain the capsule.

Preferably, the number of times of decocting with water in step (1) is 2-5, and the time of decocting with water is: the first time of decoction is 2-3 hours, and the second time of decoction is 1-2 hours.

Preferably, the concentration process in step (1) is as follows: concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35.

Preferably, the temperature of the temperature rise in the step (2) is 75-90 ℃.

Preferably, the temperature reduction in the step (2) is to reduce the temperature to 65-75 ℃.

Preferably, the equipment used for granulating in step (3) is a spray granulator.

Preferably, the rotating speed of the spray granulator in the step (3) is 300-.

Preferably, the step (3) of sieving obtains the four-yellow dysentery stopping microcapsule with the particle size of 200-.

An application of Sihuang dysentery stopping microcapsule in preparing medicine for treating and preventing livestock and poultry colibacillosis is provided.

The astragalus polysaccharide is an extract of astragalus root, one of the most representative of a plurality of bioactive polysaccharides, is a typical representative of a Chinese herbal immunopotentiator, has the functions of enhancing the immunity of organisms, resisting viruses, tumors, delaying senescence, resisting oxidation, resisting stress, regulating blood sugar and the like, can improve the taste, mask the unpleasant odor of medicaments, increase the appetite of animals, improve the immunity of the animals, strengthen the animal body and improve the disease prevention capability, and particularly has more effect when the disease resistance of the animals is reduced due to stress such as beak breaking, inoculation, group transfer, heat stress and the like.

Colibacillosis in chicken is an infectious disease with complex disease conditions, and can be regarded as virus immersion, lung and stomach heat and blood stasis and qi stagnation according to the dialectical demonstration of Chinese veterinarian, and the treatment is suitable for clearing heat and removing toxicity, activating blood and dissipating blood stasis. The damp-heat can not be removed by using antibiotics only. The formula takes the coptis chinensis, the golden cypress, the rhubarb, the isatis root and the scutellaria baicalensis as monarch drugs, has the effects of clearing heat, drying dampness, stopping dysentery, removing internal factors of damp heat, enabling the environment in an intestinal tract to be normal, and has the effects of resisting virus and sterilizing. Honeysuckle and gardenia are used as ministerial drugs, wherein the honeysuckle has the functions of clearing away heat and toxic materials and dispelling wind and heat; gardenia jasminoides ellis clears fire and toxic materials, clears heat and induces diuresis, and cools blood. The astragalus polysaccharide in the astragalus is the most representative of a plurality of bioactive polysaccharides, and has the functions of enhancing body immunity, resisting virus, resisting tumor, delaying senility, resisting oxidation, resisting stress, regulating blood sugar and the like as a typical representation of a Chinese herbal medicine immunopotentiator. The liquorice is used as a messenger drug, and has the effects of tonifying spleen and qi, relieving cough and moistening lung, relieving urgency and detoxifying, and harmonizing various drugs. The traditional Chinese medicine provided by the invention can adjust the physiological condition of the organism besides resisting virus and sterilizing, so as to treat both symptoms and root causes, and effectively utilize the nature, taste, meridian tropism and functional indication of the traditional Chinese medicine.

The beneficial technical effects of the invention are as follows:

the invention adopts the western medicine preparation of the traditional Chinese medicine, has simple preparation process, does not need to be dried again, saves the production cost, can fully extract the effective components, can cover the inherent bitter taste of the traditional Chinese medicine of the medicine by adding the auxiliary materials to prepare the micro-capsule, improves the mouth feel, and has good dissolubility and high bioavailability.

The Sihuang dysentery stopping micro-capsule has the advantages of reasonable proportion, convenient operation, good content uniformity, good stability, high yield, good taste and good treatment effect.

1) The Sihuang dysentery stopping micro-capsule provided by the invention has the effects of clearing heat, drying dampness, detoxifying, stopping dysentery, strengthening spleen and stomach, helping digestion and being safe to use by combining various traditional Chinese medicinal materials.

2) The optimal proportion of the traditional Chinese medicines is combined and astragalus polysaccharide is added as a modifier, so that the taste can be improved, the unpleasant smell of the medicines can be covered, the compliance of livestock and poultry to the medicines can be increased, the appetite of animals can be increased, the immunity of the animals can be improved, and the traditional Chinese medicines are good in dissolubility and high in bioavailability.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail by examples below. It should be understood, however, that the description herein of specific embodiments is only intended to illustrate the invention and not to limit the scope of the invention.

Example 1

A Sihuang dysentery stopping microcapsule comprises the following components in parts by weight:

28 parts of thick paste, 45 parts of PEG4000, 12 parts of PEG6000 and 15 parts of astragalus polysaccharide;

the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.

(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis, Glycyrrhrizae radix, flos Lonicerae and fructus Gardeniae in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;

(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 70 deg.C, adding the soft extract under stirring to obtain mixture;

(3) adding the mixture into a spray granulator with the rotation speed of 350r/min for granulation, and sieving to obtain the Sihuang dysentery stopping micro-capsule.

Example 2

25 parts of thick paste, 45 parts of PEG4000, 15 parts of PEG6000 and 15 parts of astragalus polysaccharide;

Example 3

20 parts of thick paste, 45 parts of PEG4000, 15 parts of PEG6000 and 20 parts of astragalus polysaccharide;

Comparative example 1

30 parts of thick paste, 50 parts of PEG4000 and 20 parts of PEG 6000; the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice, 100 parts of honeysuckle and 100 parts of gardenia.

(2) mixing PEG4000 and PEG6000, heating to 80 deg.C, stirring, cooling to 70 deg.C, and adding the soft extract while stirring to obtain mixture;

Comparative example 2

(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, cooling to 50 deg.C, and adding the soft extract under stirring to obtain mixture;

Comparative example 3

(2) mixing PEG4000, PEG6000 and Astragalus polysaccharides, heating to 80 deg.C, stirring, heating to 98 deg.C, and adding the soft extract under stirring to obtain mixture;

Comparative example 4

the thick paste is prepared from the following raw materials in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root and 100 parts of liquorice.

(1) decocting Coptidis rhizoma, cortex Phellodendri, radix et rhizoma Rhei, Scutellariae radix, radix Isatidis and Glycyrrhrizae radix in water for 2 times, 2 hr for the first time and 1 hr for the second time, mixing decoctions, filtering, and concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35;

Comparative example 5

The Sihuang dysentery stopping granules comprise the following components in parts by mass: 200 parts of coptis chinensis, 200 parts of golden cypress, 100 parts of rhubarb, 200 parts of scutellaria baicalensis, 200 parts of isatis root, 100 parts of liquorice and 10-30 parts of auxiliary materials; the auxiliary material is selected from sucrose and dextrin.

(1) decocting coptis chinensis, golden cypress, rheum officinale, scutellaria baicalensis, isatis root and liquorice in water for 2 hours for the first time and 1 hour for the second time, mixing decoctions, filtering, concentrating, and concentrating the filtrate to obtain a thick paste with the relative density of 1.32-1.35;

(2) adding sucrose and dextrin, granulating, and drying to obtain SIHUANGZHILI granule.

Test example 1: the content uniformity of the drug of the invention and the content uniformity of the drug of the common dosage form were measured, and the smaller the content uniformity, the better the content uniformity, comparing the content uniformity of baicalin in example 1 and example 5, the results are shown in table 1.

TABLE 1 content uniformity of baicalin

Example 1 the content uniformity of three batches of drug was: 1.8, 2.2 and 1.8, while the uniformity of the content of the three batches of the drug in the comparative example 5 is respectively 9.2, 11.2 and 10.0, the data show that the uniformity of the content of the drug baicalin found by the method is better than that of the drug baicalin of the invention of the common dosage form, and the content of the baicalin is required to be more than 100 percent of the marked amount according to the quality standard of the Sihuang dysentery stopping granules, namely, the content of the drug in the three batches of the common dosage form in the comparative example 5 is unqualified.

Test example 2: detecting the yield of the Sihuang dysentery stopping micro-capsule and determining the production process thereof.

1 purpose of the test: the optimal production process is determined by detecting the yield of the Sihuang dysentery stopping micro-capsule provided by the invention, so that the benefit is maximized.

2 test drugs: test products: tetrahuang dysentery stopping microcapsules (prepared according to example 1 and comparative examples 1-3).

3, test results: the yields of example 1 and comparative example 1 are best; comparative example 2 because the material temperature is too low, the mobility is bad, apt to stop up pipeline and shower nozzle, the yield is low; comparative example 3 the results are shown in table 2, in which the particles are agglomerated and the yield is low because the surface temperature of the particles is high without being rapidly cooled.

TABLE 2 recovery of Sihuang dysentery stopping micro-capsules

Test example 3: stability test of Sihuang Zhili micro-capsule (accelerated test)

1 purpose of the test: the stability of the Sihuang dysentery stopping micro-capsule provided by the invention is verified by detecting the content change of baicalin under an accelerated test condition.

2 test drugs: test products: tetra-yellow dysentery-stopping microcapsules (prepared according to examples 1 and 2, 3 batches each); all the raw materials are commercial products.

3, test method:

the test was carried out by referring to accelerated test measurement in stability of the first edition of pharmacopoeia of the people's republic of China 2015. And (3) packaging according to a market, placing for 6 months under the conditions that the temperature is 40 +/-2 ℃ and the relative temperature is 70 +/-5%, monitoring the temperature and the humidity in real time, sampling once at 1 month, 2 months, 3 months and 6 months in the test period, detecting the content of the baicalin, and comparing with a zero-hour sample.

4, test results:

under the condition of accelerated test, the content of baicalin in the four-yellow dysentery stopping micro-capsule is detected, and the test result is shown in table 3. The results show that: the content of the tetra-yellow dysentery stopping microcapsule (examples 1 and 2 of the invention) is stable and is more than 100% in the examples 1 and 2 under the condition of an accelerated test, and the test result shows that the tetra-yellow dysentery stopping microcapsule of the invention has high stability.

TABLE 3 accelerated test results of Sihuang dysentery stopping micro-capsules

Test example 4: clinical test of 'Sihuang' dysentery stopping micro-capsule

1 purpose of the test: the Sihuang dysentery stopping micro-capsule provided by the invention has the effect of treating chicken colibacillosis by detecting.

2 test drugs: test products: tetra-yellow dysentery stopping granules (microcapsules) (prepared according to example 1, comparative example 1 and comparative example 4, 1 batch each); all the raw materials are commercial products.

3, test method:

the targeted chicken, sick chicken, depressed spirit, loose feather, anorexia, and abominable. Some sick chickens have diarrhea, and feathers below cloaca are moist and dirty and sticky. Lameness. Ophthalmia, some with neurological symptoms. Chronic emaciation, slow growth, arthritic inflammation, pericarditis visualized by autopsy, hydropericardium, pericardial morbid turbidity, adhesion of internal exudates to myocardium, and cellulose perihepatitis. It shows hepatomegaly, exudation of cellulosic exudates from the liver surface, fibrinous bronchiolitis, turbid air sac, and cellulosic exudates. Granuloma, which is mainly produced in the duodenum, caecum, mesentery and liver, produces colibacillus granuloma, follicular membrane is congested and deformed, and the follicle is reddish brown or dark brown. Congestion and bleeding of the fallopian tube. Cock testis hyperemia, dyspareunia congestion, swelling, and colibacillosis were noted, and the targeted chickens were divided into four groups of 100 chickens each and were fed without the lutetium-containing diarrhea-relieving microcapsule blank test, and were fed with the dose of each of example 1, comparative example 1, and comparative example 4, mixed with the dose of each, for 10 days.

4, test results:

the results are shown in Table 4.

TABLE 4

The blank group found that targeted chickens had a mortality rate of 98% within 10 days of feeding; example 1 after feeding targeted chickens for 10 days, the mental state is good, the diet is normal, the feces are normal, the survival rate is as high as 99%, the duodenum, the caecum, the mesentery and the liver of the targeted chickens are all normal through cesarean examination, and no escherichia coli exists, which indicates that the tetra-yellow dysentery stopping microcapsules prepared in example 1 have the effect of treating the colibacillosis. After the targeted chicken in the comparative example 1 is fed for 10 days, the mental state is good, the diet is normal, the feces are normal, and the survival rate reaches 95%, but the daily feed intake of the chicken in the example 1 is about 10g more than that of the chicken in the comparative example 1, which shows that the addition of the polysaccharides from Huang's republic of food can increase the appetite; the targeted chicken of comparative example 4 was fed for 10 days and had good mental status, normal diet and normal feces, but had a survival rate of only 90% and found 3 chickens with coliform bacteria. The experiment proves that the survival rate of the example 1 is higher than that of the comparative example 4, which shows that the effect of treating colibacillosis is improved by adding honeysuckle and gardenia, and the drug resistance is low.

After the four-yellow dysentery stopping micro-capsule is used for drug administration, the mental state of sick chickens is good, the feces are normal, the feed intake is increased, and all diseases disappear.

Claims

1. The Sihuang dysentery stopping microcapsule is characterized by comprising the following components: soft extract, emulsifier and astragalus polysaccharide; the thick paste is prepared from the following raw materials: coptis root, phellodendron bark, rhubarb, scutellaria root, isatis root, liquorice, honeysuckle and gardenia.

2. The tetra yellow dysentery stopping microcapsule according to claim 1, which is characterized by comprising the following components in parts by mass: 10-30 parts of thick paste, 50-65 parts of emulsifier and 10-15 parts of astragalus polysaccharide; the thick paste is prepared from the following raw materials in parts by mass: 300 parts of coptis chinensis 200-.

3. The tetra yellow dysentery stopping microcapsule according to claim 1 or 2, wherein the emulsifier is one or two selected from PEG4000 and PEG 6000.

4. A process for preparing a tetra yellow dysentery stopping microcapsule according to any one of claims 1 to 3, which comprises the steps of:

(2) mixing emulsifier and Astragalus polysaccharides, heating and stirring, cooling, and adding the soft extract while stirring to obtain mixture;

(3) granulating the mixture, and sieving to obtain the capsule.

5. The method according to claim 4, wherein the concentration in step (1) is carried out by: concentrating the filtered supernatant under reduced pressure to obtain soft extract with relative density of 1.32-1.35.

6. The method of claim 4, wherein the stirring of step (2) is performed at 75 ℃ to 90 ℃.

7. The method for preparing the nano-particles according to claim 4, wherein the temperature reduction in the step (2) is to reduce the temperature to 65-75 ℃.

8. The method according to claim 4, wherein the granulating in step (3) is carried out by using a spray granulator.

9. The preparation method according to claim 4, wherein the rotation speed of the spray granulator in step (3) is 300-350 r/min.

10. The use of the tetra-yellow dysentery stopping microcapsule according to any one of claims 1-3 in the preparation of a medicament for treating and preventing colibacillosis in livestock and poultry.